This resource is no longer available
Social and economic factors and health behaviors alone are attributable to 70% of poor health outcomes.
Therefore, FDA guidance recommends including a diversity plan in all cases where clinical studies are required to support regulatory submission of medical products.
Watch this on-demand webinar to access 3 keys to designing representative clinical trials.